Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
45.59 ^CNY	+0.84%		+1.04%	-13.41%

17/06	Gan & Lee Pharmaceuticals.(SHSE:603087) added to SSE 180 Index	CI
17/06	Gan & Lee Pharmaceuticals.(SHSE:603087) added to Shanghai Stock Exchange 180 Value Index	CI

Gan & Lee Pharmaceutical, Ltd. has withdrawn its IPO.

January 04, 2019 at 10:30 am IST

Gan & Lee Pharmaceutical, Ltd. has withdrawn its IPO. Security Name: A Shares Security Type: Common Stock Securities Offered: 40,200,000

Latest news about Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.(SHSE:603087) added to SSE 180 Index	17/06	CI
Gan & Lee Pharmaceuticals.(SHSE:603087) added to Shanghai Stock Exchange 180 Value Index	17/06	CI
Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection	24/05	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	24/04	CI
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	26/01	MT
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	12/12	MT
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	04/12	MT
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	10/11	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	12/23/12	MT
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	18/23/18	CI
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	18/23/18	CI
Gan & Lee Pharma Advances Trial of New Insulin Product	13/23/13	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	18/23/18	CI
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	20/23/20	MT
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	20/23/20	MT
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	14/23/14	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
FDA Accepts Gan & Lee Pharma's Application for Insulin Glargine Injection	24/23/24	MT
Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from S&P Global BMI Index	19/22/19	CI
Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index	12/22/12	CI
Gan & Lee Pharmaceuticals' Insulin Injection Enters Pakistani Market	09/22/09	MT
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from Shanghai Stock Exchange 180 Value Index	09/22/09	CI

Chart Gan & Lee Pharmaceuticals.

Duration

Period

More charts

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Gan & Lee Pharmaceuticals.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.59 CNY

Average target price

63 CNY

Spread / Average Target

+38.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GAN & LEE PHARMACEUTICALS.	-13.41%	3.75B
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	42.34B
BIOGEN INC.	-13.04%	32.76B
UCB	+79.97%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-10.92%	16.31B
INCYTE CORPORATION	+1.93%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	12.23B
ALTEOGEN INC.	+177.16%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	+1.42%	8.97B

Biopharmaceuticals

Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

Gan & Lee Pharmaceutical, Ltd. has withdrawn its IPO.

Latest news about Gan & Lee Pharmaceuticals.

Chart Gan & Lee Pharmaceuticals.

Company Profile

Income Statement Evolution

Ratings for Gan & Lee Pharmaceuticals.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals